Wells Fargo lowered the firm’s price target on Baxter to $44 from $46 and keeps an Equal Weight rating on the shares. Baxter’s Q2 results were ahead of expectations on broad-based strength, but uncertainty on Novum IQ approval remains an overhang, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BAX:
- Baxter (NYSE:BAX) Stock Falls on Mixed Q2 Results, Guidance Trim
- Baxter sees FY23 adjusted EPS $2.87-$2,95, consensus $2.93
- Baxter sees Q3 adjusted EPS 78c-80c, consensus 80c
- Baxter reports Q2 adjusted EPS 55c, consensus 60c
- Notable companies reporting before tomorrow’s open
Questions or Comments about the article? Write to editor@tipranks.com